PMID- 30877709
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191114
IS  - 2233-6079 (Print)
IS  - 2233-6087 (Electronic)
IS  - 2233-6079 (Linking)
VI  - 43
IP  - 5
DP  - 2019 Oct
TI  - Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean 
      Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice.
PG  - 590-606
LID - 10.4093/dmj.2018.0134 [doi]
AB  - BACKGROUND: This study aimed to evaluate the efficacy and safety of 
      sodium-glucose cotransporter-2 (SGLT2) inhibitors in Korean patients who had 
      inadequately controlled type 2 diabetes mellitus (T2DM) in real-world clinical 
      practice. METHODS: We included 410 patients who started SGLT2 inhibitors 
      (empagliflozin or dapagliflozin) as add-on therapy or switch therapy between 
      February 2015 and June 2017. The primary efficacy endpoint was a change in 
      glycosylated hemoglobin (HbA1c) from baseline to week 12. The secondary endpoints 
      were patients achieving HbA1c <7.0% and changes in the fasting plasma glucose 
      (FPG), lipid profiles, body weight, and blood pressure (BP). RESULTS: The mean 
      HbA1c at baseline was 8.5% (8.6% in the add-on group and 8.4% in the switch 
      group). At week 12, the mean adjusted HbA1c decreased by -0.68% in the overall 
      patients (P<0.001), by -0.94% in the add-on group, and by -0.42% in the switch 
      group. Significant reductions in FPG were also observed both in the add-on group 
      and switch group (-30.3 and -19.8 mg/dL, respectively). Serum triglyceride (-16.5 
      mg/dL), body weight (-2.1 kg), systolic BP (-4.7 mm Hg), and diastolic BP (-1.3 
      mm Hg) were significantly improved in the overall patients. Approximately 18.3% 
      of the patients achieved HbA1c <7.0% at week 12. A low incidence of hypoglycemia 
      and genital tract infection was observed (6.3% and 2.2%, respectively). 
      CONCLUSION: SGLT2 inhibitors can be a suitable option as either add-on or switch 
      therapy for Korean patients with inadequately controlled T2DM.
CI  - Copyright (c) 2019 Korean Diabetes Association.
FAU - Hong, A Ram
AU  - Hong AR
AUID- ORCID: 0000-0002-2494-9902
AD  - Department of Internal Medicine, Chonnam National University Medical School, 
      Gwangju, Korea.
FAU - Koo, Bo Kyung
AU  - Koo BK
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul, Korea.
AD  - Department of Internal Medicine, Seoul Metropolitan Government Seoul National 
      University Boramae Medical Center, Seoul, Korea.
FAU - Kim, Sang Wan
AU  - Kim SW
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul, Korea.
AD  - Department of Internal Medicine, Seoul Metropolitan Government Seoul National 
      University Boramae Medical Center, Seoul, Korea.
FAU - Yi, Ka Hee
AU  - Yi KH
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul, Korea.
AD  - Department of Internal Medicine, Seoul Metropolitan Government Seoul National 
      University Boramae Medical Center, Seoul, Korea.
FAU - Moon, Min Kyong
AU  - Moon MK
AUID- ORCID: 0000-0002-5460-2846
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul, Korea.
AD  - Department of Internal Medicine, Seoul Metropolitan Government Seoul National 
      University Boramae Medical Center, Seoul, Korea. mkmoon@snu.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20190228
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
PMC - PMC6834827
OTO - NOTNLM
OT  - Blood glucose
OT  - Diabetes mellitus, type 2
OT  - Hypoglycemia
OT  - Sodium-glucose transporter 2
COIS- No potential conflict of interest relevant to this article was reported.
EDAT- 2019/03/17 06:00
MHDA- 2019/03/17 06:01
PMCR- 2019/10/01
CRDT- 2019/03/17 06:00
PHST- 2018/07/27 00:00 [received]
PHST- 2018/12/06 00:00 [accepted]
PHST- 2019/03/17 06:00 [pubmed]
PHST- 2019/03/17 06:01 [medline]
PHST- 2019/03/17 06:00 [entrez]
PHST- 2019/10/01 00:00 [pmc-release]
AID - 43.e12 [pii]
AID - 10.4093/dmj.2018.0134 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2019 Oct;43(5):590-606. doi: 10.4093/dmj.2018.0134. Epub 2019 
      Feb 28.